vs

Side-by-side financial comparison of Loews Corporation (L) and Moderna (MRNA). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $827.0M, roughly 1.2× Loews Corporation). Loews Corporation runs the higher net margin — 48.6% vs -19.7%, a 68.3% gap on every dollar of revenue. On growth, Loews Corporation posted the faster year-over-year revenue change (4.8% vs -45.4%). Loews Corporation produced more free cash flow last quarter ($426.0M vs $-880.0M). Over the past eight quarters, Loews Corporation's revenue compounded faster (7.9% CAGR vs -45.0%).

Loews Corporation is a diversified US-based conglomerate that operates across multiple key industry segments through its subsidiaries. Its core business lines include property and casualty insurance, natural gas pipeline transportation, hospitality services, and upstream oil and gas exploration and production, primarily serving commercial, consumer and industrial clients across North American markets.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

L vs MRNA — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.2× larger
MRNA
$1.0B
$827.0M
L
Growing faster (revenue YoY)
L
L
+50.3% gap
L
4.8%
-45.4%
MRNA
Higher net margin
L
L
68.3% more per $
L
48.6%
-19.7%
MRNA
More free cash flow
L
L
$1.3B more FCF
L
$426.0M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
L
L
Annualised
L
7.9%
-45.0%
MRNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
L
L
MRNA
MRNA
Revenue
$827.0M
$1.0B
Net Profit
$402.0M
$-200.0M
Gross Margin
79.6%
Operating Margin
65.4%
-25.6%
Net Margin
48.6%
-19.7%
Revenue YoY
4.8%
-45.4%
Net Profit YoY
115.0%
-1638.5%
EPS (diluted)
$1.93
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
L
L
MRNA
MRNA
Q4 25
$827.0M
Q3 25
$732.0M
$1.0B
Q2 25
$769.0M
Q1 25
$846.0M
Q4 24
$789.0M
$966.0M
Q3 24
$683.0M
$1.9B
Q2 24
$711.0M
Q1 24
$710.0M
Net Profit
L
L
MRNA
MRNA
Q4 25
$402.0M
Q3 25
$504.0M
$-200.0M
Q2 25
$391.0M
Q1 25
$370.0M
Q4 24
$187.0M
$-1.1B
Q3 24
$401.0M
$13.0M
Q2 24
$369.0M
Q1 24
$457.0M
Gross Margin
L
L
MRNA
MRNA
Q4 25
Q3 25
79.6%
Q2 25
Q1 25
Q4 24
23.5%
Q3 24
72.4%
Q2 24
Q1 24
Operating Margin
L
L
MRNA
MRNA
Q4 25
65.4%
Q3 25
94.1%
-25.6%
Q2 25
70.1%
Q1 25
60.8%
Q4 24
23.8%
-129.0%
Q3 24
80.5%
-3.8%
Q2 24
71.3%
Q1 24
88.6%
Net Margin
L
L
MRNA
MRNA
Q4 25
48.6%
Q3 25
68.9%
-19.7%
Q2 25
50.8%
Q1 25
43.7%
Q4 24
23.7%
-115.9%
Q3 24
58.7%
0.7%
Q2 24
51.9%
Q1 24
64.4%
EPS (diluted)
L
L
MRNA
MRNA
Q4 25
$1.93
Q3 25
$2.43
$-0.51
Q2 25
$1.87
Q1 25
$1.74
Q4 24
$0.87
$-2.91
Q3 24
$1.82
$0.03
Q2 24
$1.67
Q1 24
$2.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
L
L
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$6.0B
$1.1B
Total DebtLower is stronger
$8.4B
Stockholders' EquityBook value
$18.7B
$9.3B
Total Assets
$86.3B
$12.1B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
L
L
MRNA
MRNA
Q4 25
$6.0B
Q3 25
$5.4B
$1.1B
Q2 25
$4.5B
Q1 25
$4.4B
Q4 24
$4.6B
$1.9B
Q3 24
$5.2B
$1.6B
Q2 24
$4.9B
Q1 24
$5.4B
Total Debt
L
L
MRNA
MRNA
Q4 25
$8.4B
Q3 25
$8.4B
Q2 25
$7.9B
Q1 25
$8.4B
Q4 24
$8.9B
Q3 24
$8.8B
Q2 24
$8.6B
Q1 24
$8.4B
Stockholders' Equity
L
L
MRNA
MRNA
Q4 25
$18.7B
Q3 25
$18.3B
$9.3B
Q2 25
$17.5B
Q1 25
$17.2B
Q4 24
$17.1B
$10.9B
Q3 24
$17.4B
$11.9B
Q2 24
$16.4B
Q1 24
$16.2B
Total Assets
L
L
MRNA
MRNA
Q4 25
$86.3B
Q3 25
$85.9B
$12.1B
Q2 25
$84.7B
Q1 25
$83.1B
Q4 24
$81.9B
$14.1B
Q3 24
$83.6B
$15.8B
Q2 24
$81.1B
Q1 24
$80.9B
Debt / Equity
L
L
MRNA
MRNA
Q4 25
0.45×
Q3 25
0.46×
Q2 25
0.45×
Q1 25
0.49×
Q4 24
0.52×
Q3 24
0.51×
Q2 24
0.52×
Q1 24
0.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
L
L
MRNA
MRNA
Operating Cash FlowLast quarter
$617.0M
$-847.0M
Free Cash FlowOCF − Capex
$426.0M
$-880.0M
FCF MarginFCF / Revenue
51.5%
-86.6%
Capex IntensityCapex / Revenue
23.1%
3.2%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$2.7B
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
L
L
MRNA
MRNA
Q4 25
$617.0M
Q3 25
$920.0M
$-847.0M
Q2 25
$1.0B
Q1 25
$736.0M
Q4 24
$941.0M
$825.0M
Q3 24
$934.0M
$-1.6B
Q2 24
$952.0M
Q1 24
$198.0M
Free Cash Flow
L
L
MRNA
MRNA
Q4 25
$426.0M
Q3 25
$764.0M
$-880.0M
Q2 25
$872.0M
Q1 25
$638.0M
Q4 24
$767.0M
$303.0M
Q3 24
$794.0M
$-1.7B
Q2 24
$793.0M
Q1 24
$39.0M
FCF Margin
L
L
MRNA
MRNA
Q4 25
51.5%
Q3 25
104.4%
-86.6%
Q2 25
113.4%
Q1 25
75.4%
Q4 24
97.2%
31.4%
Q3 24
116.3%
-92.2%
Q2 24
111.5%
Q1 24
5.5%
Capex Intensity
L
L
MRNA
MRNA
Q4 25
23.1%
Q3 25
21.3%
3.2%
Q2 25
17.4%
Q1 25
11.6%
Q4 24
22.1%
54.0%
Q3 24
20.5%
8.1%
Q2 24
22.4%
Q1 24
22.4%
Cash Conversion
L
L
MRNA
MRNA
Q4 25
1.53×
Q3 25
1.83×
Q2 25
2.57×
Q1 25
1.99×
Q4 24
5.03×
Q3 24
2.33×
-120.46×
Q2 24
2.58×
Q1 24
0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

L
L

Transportation And Storage Of Natural Gas And NG Ls And Ethane Supply And Transportation Services$601.0M73%
Lodging And Related Services$226.0M27%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons